Failure of recognition of drug-induced parkinsonism in the elderly

被引:70
作者
Esper, Christine D. [1 ]
Factor, Stewart A. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Neurol, Wesley Woods Hlth Ctr, Atlanta, GA 30329 USA
关键词
Parkinson's disease/parkinsonism; drug-induced parkinsonism; atypical antipsychotics; metoclopramide; elderly; diagnosis;
D O I
10.1002/mds.21854
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Our objective was to evaluate the ability of neurologists to recognize and diagnose drug-induced Parkinsonism (DIP) in the elderly. DIP is a diagnostic challenge because it can be indistinguishable from Parkinson's disease, especially in the elderly. It is frequently under-recognized by psychiatrists and primary care physicians. Atypical antipsychotics (AA) are advertised for their low propensity to cause DIP. This may add to problems with recognition. We performed a retrospective record review of consecutive new parkinsonian patients seen over 2 years in a movement disorders clinic to examine the frequency, causative agents, and diagnostic accuracy of DIP by physicians, particularly neurologists. Of 354 Parkinsonian patients evaluated, 24 (6.8%) had DIP, 46% of these were due to AA and 29% were caused by metoclopramide. Of the 24 patients with DIP, only one was previously diagnosed accurately according to records. Nineteen patients (79%) were previously evaluated by a neurologist, and none of them was diagnosed with DIP. The primary reason for failure to recognize DIP relates to under-recognition of AA as possible cause. A majority remained on the inciting agents while dopaminergic drugs were prescribed. DIP was reversible when the inciting drug was stopped. DIP is a common form of parkinsonism and is under-recognized, even by neurologists. AA and metoclopramide do not appear to be well-known to cause DIP. Cessation of the offending agent results in improvement of symptoms and would eliminate the need for dopaminergic agents, which are known to commonly cause side effects in the elderly. (c) 2007 Movement Disorder Society.
引用
收藏
页码:401 / 404
页数:4
相关论文
共 30 条
[1]   Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol [J].
Andrezina, Raisa ;
Josiassen, Richard C. ;
Marcus, Ronald N. ;
Oren, Dan A. ;
Manos, George ;
Stock, Elyse ;
Carson, William H. ;
Iwamoto, Taro .
PSYCHOPHARMACOLOGY, 2006, 188 (03) :281-292
[2]   NEUROLEPTIC DRUG EXPOSURE AND TREATMENT OF PARKINSONISM IN THE ELDERLY - A CASE-CONTROL STUDY [J].
AVORN, J ;
BOHN, RL ;
MOGUN, H ;
GURWITZ, J ;
MONANE, M ;
EVERITT, D ;
WALKER, A .
AMERICAN JOURNAL OF MEDICINE, 1995, 99 (01) :48-54
[3]   A SURVEY OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS [J].
AYD, FJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1961, 175 (12) :1054-&
[4]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[5]   Novel therapies for treating acute agitation [J].
Currier, GW ;
Allen, MH ;
Bunney, EB ;
Daniel, DG ;
Francis, A ;
Jagoda, A ;
Zimbroff, D .
JOURNAL OF EMERGENCY MEDICINE, 2004, 27 (04) :S13-S18
[6]   Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease [J].
De Deyn, PP ;
Carrasco, MM ;
Deberdt, W ;
Jeandel, C ;
Hay, DP ;
Feldman, PD ;
Young, CA ;
Lehman, DL ;
Breier, A .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (02) :115-126
[7]   The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up [J].
Fernandez, HH ;
Krupp, B ;
Friedman, JH .
NEUROLOGY, 2001, 56 (06) :805-807
[8]  
Friedman IH, 2005, DRUG INDUCED MOVEMEN, P103
[9]  
Friedman JH, 2000, MOVEMENT DISORD, V15, P201, DOI 10.1002/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO
[10]  
2-D